# SWOG-1216 (NCT01809691)

> S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: orteronel
- Indication: newly diagnosed metastatic hormone-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01809691
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: SWOG Cancer Research Network
- Conditions: Prostate Cancer
- Interventions: TAK-700; Bicalutamide
- Enrollment: 1313
- Primary outcome: Overall Survival

## Indexed commentary on SWOG-1216 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 40
- YouTube: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=swog-1216-nct01809691

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01809691", "email": "<work email>"}; the inbox owner confirms by the emailed link.